SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.2899

Change

0.00 (-0.03)%

Market Cap

N/A

Volume

3.99K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-0.27 (-0.35%)

USD 242.54B
AMGN Amgen Inc

-4.69 (-1.40%)

USD 180.33B
SNY Sanofi ADR

+0.19 (+0.33%)

USD 144.83B
GILD Gilead Sciences Inc

-0.20 (-0.24%)

USD 104.50B
BIIB Biogen Inc

-1.69 (-0.86%)

USD 29.04B
GRFS Grifols SA ADR

-0.10 (-1.14%)

USD 6.96B
AMRN Amarin Corporation PLC

+0.01 (+2.32%)

USD 0.23B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.05 (+4.72%)

USD 0.02B
SCLX Scilex Holding Company

+0.03 (+4.44%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.47% 30% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.47% 30% F 25% F
Trailing 12 Months  
Capital Gain -84.58% 11% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.58% 11% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.73% 44% F 26% F
Dividend Return -10.73% 44% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.62% 22% F 38% F
Risk Adjusted Return -23.52% 44% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector